Literature DB >> 34329574

Rituximab biosimilars for B-cell lymphomas: a decade of real-world experience from India.

Reena Nair1, Vivek S Radhakrishnan2, Mohandas K Mallath3.   

Abstract

Entities:  

Year:  2021        PMID： 34329574     DOI： 10.1016/S2352-3026(21)00212-X

Source DB:  PubMed          Journal:  Lancet Haematol        ISSN： 2352-3026            Impact factor:   18.959


× No keyword cloud information.
  3 in total

1.  Diffuse Large B-Cell Lymphoma: Clinical Presentation and Treatment Outcomes From the OncoCollect Lymphoma Registry.

Authors:  Reena Nair; Dinesh Bhurani; Senthil Rajappa; Asha Kapadia; Rakesh Reddy Boya; Subramanian Sundaram; Hari Menon; Ganapathi S Raman; Arun Seshachalam; Ramesh Nimmagadda
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 6.244

Review 2.  Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors.

Authors:  Ming Cai; Wei-Jian Ni; Ying-Hong Wang; Jing-Ji Wang; Hong Zhou
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

3.  Editorial: Real World Outcomes of Lymphoma From India.

Authors:  Lalit Kumar; Naresh Kn; Sumeet Gujral; Padmaj Kulkarni; Martin R Stockler; Reena Nair
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.